The Program for Research on Vaccine Effectiveness (PROVE) in Africa was established in 2022 through a partnership between the Infectious Diseases Institute (IDI) and the African Forum for Research and Education in Health (AFREHealth). PROVE is the implementation science pillar of the Saving Lives and Livelihoods (SLL) program, an initiative of the Africa Centres for Disease Control and Prevention (Africa CDC) and the Mastercard Foundation. The PROVE program focuses on rolling out a research protocol across 13 Africa Union [AU] member states to study the COVID-19 vaccine effectiveness, vaccine uptake determinants, and the impact of the pandemic on health systems.

Geographical Coverage: In-country NPHIs/MOH and local institutions in the PROVE program in Africa

Leveraging National Public Health Institutions and Academia

PROVE leverages a collaborative model of the National Public Health Institutes (NPHIs), in-country academic institutions, and local implementing partners to translate public health research into tangible policy and practice in African Union member states.

PROVE’s capacity-building initiatives:

  • The program empowers the health workforce to implement research initiatives, research data management and utilization through training.
  • PROVE supports the implementing country teams to set up research infrastructure for current and future utilization.
  • Strengthening health research networks in Africa through the health security academic consortium.
  • Facilitating effective dissemination and knowledge exchange of public health research with stakeholders, partners, and scientists across Africa.